Who
David Soergel
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Madrigal Pharmaceuticals; Sr. VP,Clinical Dev. & CMO, Trevena.
In numbers
- Trades disclosed
- 19
- Buys
- 3
- Sells
- 3
- Bought
- $12K
- Sold
- $2.2M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 20 Feb 2014
- Last trade
- 1 Jun 2026
- Last filed
- 1 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 1 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $517K1,042 at $495.74 | filing |
| 1 Jun 2026filed 1 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $517K1,042 at $495.74 | filing |
| 18 May 2026filed 18 May 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $435K844 at $515.90 | filing |
| 18 May 2026filed 18 May 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $435K844 at $515.90 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,374 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,467 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,467 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,374 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,839 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —7,545 at $0.00 | filing |
| 2 Mar 2017filed 3 Mar 2017 | Trevenaoption or derivative | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 6 Jan 2017filed 6 Jan 2017 | Trevenaoption or derivative | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 3 Mar 2016filed 7 Mar 2016 | Trevenaoption or derivative | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 10 Dec 2015filed 11 Dec 2015 | Trevena | SEC FORM 4 Sold | $287K27,217 at $10.55 | filing |
| 17 Mar 2015filed 19 Mar 2015 | Trevenaoption or derivative | SEC FORM 4 Code A | —87,500 at $0.00 | filing |
| 10 Dec 2014filed 10 Dec 2014 | Trevena | SEC FORM 4 Bought | $5,0001,250 at $4.00 | filing |
| 10 Dec 2014filed 10 Dec 2014 | Trevena | SEC FORM 4 Bought | $5,0001,250 at $4.00 | filing |
| 9 Dec 2014filed 10 Dec 2014 | Trevena | SEC FORM 4 Bought | $1,985500 at $3.97 | filing |
| 20 Feb 2014filed 11 Mar 2014 | Trevenaoption or derivative | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name David Soergel; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.